News Sentiment

EBS sentiment intelligence

Emergent Biosolutions Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 54 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 8.05 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-2.8% over one week, -3.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Emergent BioSolutions (EBS) AGM 2026 Summary

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.8% Price reacting lower
Trend fit Trend inactive -3.2% over four weeks
Fair value 14.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 36
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
TradingView 6
simplywall.st 6
GlobeNewswire 5
TradingKey 4
Market source 4
Stocktwits 3
MT Newswires 3

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 11
Deals and strategy 8
Balance sheet 3
Regulatory and legal 2
Analyst action 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Quartr Direct company coverage

Emergent BioSolutions (EBS) AGM 2026 Summary

The Emergent BioSolutions (EBS) 2026 AGM highlighted substantial progress on its multi-year turnaround plan, achieving improved financial results in 2025 including strong adjusted EBITDA, increased cash flow, and reduced debt. The agenda covered director elections, auditor ratifi

Tone
Positive 81/100
Event
Balance sheet
Published
16 Jul 2026 22:41
Source
Quartr
Quartr Direct company coverage

Emergent BioSolutions (EBS) Proxy filing Summary

Emergent BioSolutions (EBS) has released a proxy filing summary detailing their annual meeting scheduled for April 29, 2026. Shareholders of record as of March 6, 2026, are eligible to vote on various proposals, with a voting deadline of April 28, 2026. The company encourages rev

Tone
Positive 70/100
Event
Market update
Published
16 Jul 2026 16:41
Source
Quartr
Quiver Quantitative Direct company coverage

Lobbying Update: $510,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed

Emergent BioSolutions Inc. (EBS) recently disclosed $510,000 in lobbying expenditures for Q2 2026, targeting legislation related to pandemic preparedness, medical countermeasures, and opioid crisis interventions. Insiders at EBS have primarily sold stock in the past six months, w

Tone
Negative 38/100
Event
Market update
Published
14 Jul 2026 20:08
Source
Quiver Quantitative
TradingView Direct company coverage

EBS5025998 Bond Profile — Key Metrics

This article provides key metrics for the Emergent BioSolutions Inc. 3.875% 15-AUG-2028 bond, identified as EBS5025998. It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. Furthermore, it offers a brief description of Emergent BioSolu

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 18:37
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Emergent BioSolutions Inc. – LS:A0LC2W

This page provides information on the forward price-to-sales ratio for Emergent BioSolutions Inc. (LS:A0LC2W). It seems to be a financial data entry page, possibly from a financial charting and analysis platform, showing market data and company information, but the specific value

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 09:10
Source
TradingView
GuruFocus Direct company coverage

Insider Sell: Paul Williams Sells 3,000 Shares of Emergent BioSo

Paul Williams, Senior Vice President at Emergent BioSolutions Inc (EBS), sold 3,000 shares of the company on July 1, 2026. This transaction brings his total ownership to 159,098 shares. Over the last year, there have been 12 insider sells and no insider buys at EBS, and the stock

Tone
Negative 30/100
Event
Market update
Published
02 Jul 2026 18:10
Source
GuruFocus
Investing.com Direct company coverage

Emergent BioSolutions SVP Williams sells $25,200 in common stock

Paul Anthony Williams, Senior Vice President of Products Business at Emergent BioSolutions Inc., sold 3,000 shares of the company's common stock for $25,200 on July 1, 2026. The sale was executed at a weighted average price of $8.40 per share, pursuant to a pre-arranged trading p

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 17:10
Source
Investing.com
Stock Titan Direct company coverage

Emergent BioSolutions (EBS) SVP sells 3,000 shares under plan

Emergent BioSolutions Inc.'s Senior Vice President, Paul Anthony Williams, sold 3,000 shares of common stock on July 1, 2026, at a weighted average price of $8.40 per share, totaling $25,200. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established

Tone
Negative 38/100
Event
Market update
Published
02 Jul 2026 17:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Emergent BioSolutions SVP Williams sells $25,200 in common stock By Investing.com

Paul Anthony Williams, Senior Vice President of Products Business at Emergent BioSolutions Inc., sold 3,000 shares of company stock for $25,200 on July 1, 2026, at an average price of $8.40 per share. This sale was conducted under a pre-arranged trading plan. Following the transa

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 17:10
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 4 Emergent Biosolutions Inc For: 2 July By Investing.com

This article from Investing.com announces the filing of a Form 4 by Emergent Biosolutions Inc. on July 2nd. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of the company's s

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 17:10
Source
Investing.com Canada
Stock Titan Direct company coverage

[144] Emergent BioSolutions Inc. SEC Filing

Emergent BioSolutions Inc. (EBS) has filed a Form 144 Notice of Proposed Sale of Securities with the SEC. The filing indicates a proposed sale of 3,000 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $25,205.40. T

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:39
Source
Stock Titan
Finviz Direct company coverage

EBS - Emergent Biosolutions Inc Options

This article provides a detailed financial overview of Emergent Biosolutions Inc (EBS), including its stock performance, market valuation, income statement, balance sheet ratios, and analyst recommendations. It highlights key financial metrics such as market cap, sales, EPS, and

Tone
Negative 42/100
Event
Earnings
Published
30 Jun 2026 12:10
Source
Finviz
www.marketscreener.com Direct company coverage

Emergent BioSolutions Secures Contract Modification Valued At Approximately USD 52.7 Million From The United States Department Of Health And Human Services To Supply ACAM2000

Emergent BioSolutions has secured a contract modification worth approximately USD 52.7 million from the U.S. Department of Health and Human Services to supply its ACAM2000 vaccine. This vaccine, which protects against smallpox and mpox, along with ancillaries and diluent replacem

Tone
Positive 72/100
Event
Deals and strategy
Published
29 Jun 2026 16:41
Source
www.marketscreener.com
Stock Titan Direct company coverage

Emergent BioSolutions (NYSE: EBS) lands $52.7M U.S. ACAM2000 contract

Emergent BioSolutions secured a $52.7 million contract modification from the U.S. Administration for Strategic Preparedness and Response to supply its ACAM2000 smallpox and mpox vaccine, related ancillaries, and diluent replacement lots. This modification, designated Option Year

Tone
Positive 80/100
Event
Deals and strategy
Published
29 Jun 2026 15:41
Source
Stock Titan
Stock Titan Direct company coverage

U.S. government adds $52.7M ACAM2000 order for smallpox preparedness

Emergent BioSolutions (NYSE: EBS) secured a $52.7 million contract modification from the U.S. government for its ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine. This order, part of an existing 10-year agreement, aims to bolster U.S. preparedness against smallpox a

Tone
Positive 73/100
Event
Deals and strategy
Published
29 Jun 2026 13:41
Source
Stock Titan
Moomoo Direct company coverage

Emergent BioSolutions | 8-K: Current report

This article is a current report (8-K filing) from Emergent BioSolutions. It indicates that further details about the report can be found by accessing the document linked within the content.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:41
Source
Moomoo
TradingView Direct company coverage

Price to sales forward of Emergent BioSolutions Inc. – NYSE:EBS

This article provides financial information for Emergent BioSolutions Inc. (NYSE: EBS), specifically focusing on its forward price to sales metric. It appears to be a data point or a financial snapshot from a platform like TradingView, with no further analytical content.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:11
Source
TradingView
TradingView Direct company coverage

Emergent BioSolutions Inc. Actuals & Estimates (NYSE:EBS)

This article provides an overview of Emergent BioSolutions Inc. (NYSE: EBS), detailing its financial actuals and estimates, stock performance, and analyst forecasts. It covers key financial metrics like revenue, net income, and EBITDA, along with stock volatility, market capitali

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Emergent BioSolutions Inc. – NYSE:EBS

This article displays information regarding the Price to Earnings Forward for Emergent BioSolutions Inc. (NYSE: EBS). It is presented as a financial data point without further analysis or contextual details. The page seems to be a static data point from a financial platform like

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 02:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Emergent BioSolutions Inc. – BOATS:EBS

This article provides the title and stock symbol for Emergent BioSolutions Inc. (EBS) within the context of its enterprise value to revenue forward. It appears to be a stub or a section of a larger financial data page on TradingView, focusing on the company's financial metrics. T

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 00:41
Source
TradingView
TradingKey Direct company coverage

Emergent BioSolutions Inc (EBS) Valuation: PE, PB & Fair Value Analysis

Emergent BioSolutions Inc (EBS) currently has a valuation score of 9.26, ranking 38th out of 157 in the Pharmaceuticals industry. The article highlights its current P/E ratio of -59.94, which is significantly below its recent high but above its recent low. Key valuation metrics l

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 09:40
Source
TradingKey
TradingKey Direct company coverage

Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Emergent BioSolutions Inc (EBS), detailing its support and resistance levels, indicator analysis, and moving averages. The stock is currently trading between a resistance of $9.17 and a support of $7.33, making it suitable for range-b

Tone
Negative 30/100
Event
Market update
Published
18 Jun 2026 09:40
Source
TradingKey
TradingKey Direct company coverage

Emergent BioSolutions Inc (EBS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Emergent BioSolutions Inc (EBS), categorized by business segments and regional contributions. Data for various fiscal years and quarters is presented, highlighting key revenue streams like Commercial Product sales, MCM Produc

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 18:39
Source
TradingKey
TradingKey Direct company coverage

Emergent BioSolutions Inc (EBS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Emergent BioSolutions Inc (EBS) stock, focusing on its dividend history and stock splits. It notes that the company has distributed no dividends over the past five years and has no recorded stock split data. The page also presents current stoc

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 18:39
Source
TradingKey
AD HOC NEWS Direct company coverage

Emergent BioSolutions Stock (US29089Q1058): Earnings Picture And Balance Sheet Under The Microscope

Emergent BioSolutions is currently navigating a challenging period characterized by weak earnings, high leverage, and a major restructuring effort following a difficult 2024. The company is actively shifting its focus from lower-margin contract manufacturing towards core medical

Tone
Negative 29/100
Event
Earnings
Published
16 Jun 2026 16:18
Source
AD HOC NEWS
Stock Titan Direct company coverage

Emergent BioSolutions (EBS) SVP has 694 shares withheld for RSU taxes

Emergent BioSolutions Inc.'s SVP of Products Business, Paul Anthony Williams, had 694 shares of common stock withheld at $8.00 per share to cover tax obligations upon the vesting of restricted stock units. This transaction was a routine tax-related disposition, not an open-market

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 15:39
Source
Stock Titan